Building out its advanced gene sequencing technology, Shenzhen-based GeneMind Biosciences has successfully raised $84.0M in new funding. The company, established in 2012, is a "hard tech" enterprise specializing in the R&D and manufacturing of molecular diagnostic upstream platforms, aiming to foster a precision medicine ecosystem.
GeneMind is particularly known for its GenoCare single-molecule sequencing platform, which was the first globally to pass medical device clinical trials, alongside its high-throughput GenoLab system, offering comprehensive instrument-to-software solutions.

















